ClearPoint Neuro, Inc.
Business
ClearPoint Neuro develops and commercializes minimally invasive neurosurgical systems including the ClearPoint navigation platform, Prism laser ablation system, and IRRAflow intracranial fluid management system. The company sells reusable hardware and disposable consumables to hospitals and neurosurgeons. It also provides preclinical and clinical development services to pharmaceutical partners developing gene and cell therapies for neurological disorders, generating revenue through product sales, consulting, and partnership arrangements.
Summary from 10-K filed 2026-03-17
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 37 | 31 | 24 | 21 | 16 | |
| Cost of revenue | 14 | 12 | 10 | 7 | 5 | |
| Gross profit | 23 | 19 | 14 | 14 | 11 | |
| Research and development costs | 14 | 12 | 12 | 11 | 9 | |
| Sales and marketing expenses | 16 | 14 | 13 | 9 | 7 | |
| General and administrative expenses | 16 | 12 | 12 | 10 | 8 | |
| Operating loss | −24 | −20 | −22 | −16 | −13 | |
| Other expense, net | −146,000 | −40,000 | −29,000 | −22,000 | −63,000 | |
| Interest income | 1 | 1 | — | — | — | |
| Interest expense | −2 | −518,000 | — | — | — | |
| Net loss before income taxes | −25 | −19 | — | — | — | |
| Income tax expense | 55,000 | 12,000 | — | — | — | |
| Net loss | −26 | −19 | −22 | −16 | −14 | |
| Basic (in dollars per share) | −0.9 | −0.7 | −0.9 | −0.68 | −0.69 | |
| Diluted (in dollars per share) | −0.9 | −0.7 | −0.9 | −0.68 | −0.69 | |
| Basic (in shares) | 28 | 27 | 25 | 24 | 21 | |
| Diluted (in shares) | 28 | 27 | 25 | 24 | 21 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 46 | 20 | 23 | 28 | 54 | |
| Accounts receivable, net | 7 | 5 | 3 | 3 | 2 | |
| Inventory, net | 8 | 7 | 8 | 9 | 5 | |
| Prepaid expenses and other current assets | 3 | 2 | 2 | 2 | 508,000 | |
| Total current assets | 64 | 33 | 36 | 51 | 62 | |
| Property and equipment, net | 3 | 2 | 1 | 806,000 | 539,000 | |
| Operating lease, right-of-use assets | 8 | 3 | 4 | 2 | 2 | |
| Goodwill | 7 | 0 | — | — | — | |
| Intangible assets, net | 14 | 0 | — | — | — | |
| Other assets | 2 | 735,000 | 109,000 | 131,000 | 125,000 | |
| Total assets | 98 | 39 | 43 | 55 | 66 | |
| Accounts payable | 1 | 1 | 393,000 | 272,000 | 427,000 | |
| Accrued compensation | 4 | 5 | 3 | 3 | 3 | |
| Other accrued liabilities | 3 | 1 | 1 | 2 | 537,000 | |
| Operating lease liabilities, current portion | 694,000 | 557,000 | 424,000 | 561,000 | 507,000 | |
| Contract liabilities, current portion | 2 | 2 | — | — | — | |
| Total current liabilities | 11 | 10 | 7 | 7 | 5 | |
| Operating lease liabilities, net of current portion | 8 | 3 | 4 | 2 | 2 | |
| Contract liabilities, net of current portion | 581,000 | 436,000 | — | — | — | |
| Long-term notes payable, net | 49 | 0 | — | — | — | |
| Deferred tax liabilities, net | 354,000 | 0 | — | — | — | |
| Other long-term liabilities | 489,000 | 0 | — | — | — | |
| Total liabilities | 70 | 14 | 21 | 19 | 17 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.01 par value; 25,000,000 shares authorized at December 31, 2025 and 2024; none issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.01 par value; 90,000,000 shares authorized at December 31, 2025 and 2024; 29,368,760 and 27,617,415 shares issued and outstanding at December 31, 2025 and 2024, respectively | 294,000 | 276,000 | 247,000 | 246,000 | 237,000 | |
| Additional paid-in capital | 239 | 216 | 193 | 187 | 182 | |
| Shares to be issued | 6 | 0 | — | — | — | |
| Accumulated deficit | −217 | −191 | −172 | −150 | −134 | |
| Total stockholders equity | 28 | 25 | 21 | 37 | 49 | |
| Total liabilities and stockholders equity | 98 | 39 | 43 | 55 | 66 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Allowance for credit losses (recoveries) | 21,000 | −296,000 | 1 | −117,000 | 202,000 | |
| Depreciation and amortization | 814,000 | 980,000 | 626,000 | 244,000 | 159,000 | |
| Amortization of intangible assets | 168,000 | 0 | — | — | — | |
| Share-based compensation | 8 | 7 | 6 | 4 | 2 | |
| Payment-in-kind interest | 908,000 | 0 | — | 0 | 325,000 | |
| Amortization of debt issuance costs and original issue discounts | 83,000 | 51,000 | 57,000 | 55,000 | 100,000 | |
| Amortization of lease right of use assets, net of accretion in lease liabilities | 1 | 923,000 | 831,000 | 533,000 | 533,000 | |
| Accounts receivable | −268,000 | −1 | −2 | −211,000 | −658,000 | |
| Inventory, net | −103,000 | 743,000 | 1 | −4 | −2 | |
| Prepaid expenses and other current assets | −397,000 | 262,000 | −113,000 | −1 | −264,000 | |
| Other assets | −195,000 | −39,000 | 22,000 | −6,000 | −66,000 | |
| Accounts payable and accrued expenses | −8 | 3 | −649,000 | 2 | 1 | |
| Lease liabilities | −1 | −869,000 | −755,000 | −541,000 | — | |
| Contract liabilities | −319,000 | −597,000 | — | — | — | |
| Net cash flows from operating activities | −24 | −9 | −14 | −16 | −13 | |
| Cash acquired in business combination, net of cash paid | 1 | 0 | — | — | — | |
| Purchases of property and equipment | −522,000 | −275,000 | −717,000 | −253,000 | −168,000 | |
| Net cash flows from investing activities | 615,000 | −275,000 | 9 | −11 | −168,000 | |
| Proceeds from offerings of common stock, net of offering costs | 3 | 16 | 0 | 0 | 47 | |
| Proceeds from issuance of notes payable, net of financing costs and discount | 48 | 0 | — | — | — | |
| Repayment of 2020 senior secured convertible note | 0 | −10 | 0 | — | — | |
| Proceeds from stock option exercises | 127,000 | 21,000 | 0 | — | — | |
| Payments for taxes related to net share settlement of equity awards | −2 | −424,000 | −210,000 | −336,000 | −599,000 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 559,000 | 443,000 | 506,000 | 477,000 | 224,000 | |
| Net cash flows from financing activities | 50 | 6 | 296,000 | 409,000 | 47 | |
| Net change in cash, cash equivalents and restricted cash | 27 | −3 | −4 | −26 | 34 | |
| Income taxes | 69,000 | 62,000 | 0 | 0 | 0 | |
| Interest | 908,000 | 480,000 | 743,000 | 523,000 | 597,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ClearPoint Neuro, Inc.'s CIK number?
ClearPoint Neuro, Inc.'s SEC CIK number is 0001285550 (1285550). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ClearPoint Neuro, Inc.'s SEC filings?
All of ClearPoint Neuro, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ClearPoint Neuro, Inc. last report earnings?
ClearPoint Neuro, Inc. (CLPT) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-221596). This is ClearPoint Neuro, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ClearPoint Neuro, Inc.'s most recent earnings 8-K?
ClearPoint Neuro, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001193125-26-221596. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ClearPoint Neuro, Inc.'s latest earnings 8-K →
Look up any company's CIK number →